Technology
Health
Pharmaceutical

Acasti Pharma

$1.07
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.

$0.00 (0.00%) Pre-Market
$0.00 (0.00%) Pre-Market

Why Robinhood?

You can buy or sell Acasti Pharma and other stocks, options, ETFs, and crypto commission-free!

About

Acasti Pharma, Inc. engages in the development and commercialization of pharmaceutical applications of its licensed rights for cardiovascular diseases. It focuses on the research of prescription drugs using omega-3, fatty acids derived from krill oil. Read More The company was founded by Henri Harland on February 1, 2002 and is headquartered in Laval, Canada.

Employees
Headquarters
Laval, Québec
Founded
2002
Market Cap
83.60M
Price-Earnings Ratio
Dividend Yield
Average Volume
569.19K
High Today
$1.08
Low Today
$1.05
Open Price
$1.06
Volume
166.57K
52 Week High
$1.80
52 Week Low
$0.4333

Collections

Technology
Health
Pharmaceutical
2013 IPO
Canada
North America
Female CEOs

News

Simply Wall StMar 8

Introducing Acasti Pharma (CVE:ACST), The Stock That Tanked 90%

It is a pleasure to report that the Acasti Pharma Inc. (CVE:ACST) is up 56% in the last quarter. But that doesn’t change the fact that the returns over the last half decade have been stomach churning. Like a ship taking on water, the share price has sunk 90% in that time. So we don’t gain too much confidence from the recent recovery. The million dollar question is whether the company can justify a long term recovery. While a drop like that is definitely a body blow, money isn’t as important as health and h...

311
MarketBeatMar 3

Stock Price, News, & Analysis for Acasti Pharma

Acasti Pharma Inc., a biopharmaceutical company, focuses on the research, development, and commercialization of prescription drugs for the treatment of cardiovascular diseases. Its lead product candidate is CaPre, an omega-3 phospholipid therapeutic that is in Phase III clinical trial to treat patients with hypertriglyceridemia. The company was incorporated in 2002 and is headquartered in Laval, Canada. MarketBeat Community Rating for Acasti Pharma (CVE ACST) Community Ranking: 2.7 out of 5 ( ) Outperform...

29

Earnings

-$0.47
-$0.21
$0.06
$0.32
Q1 2018
Q2 2018
Q3 2018
Q4 2018
Q1 2019
Q2 2019
Q3 2019
Q4 2019
Estimated
Actual
$0.32 per share
All investments involve risk and the past performance of a security, or financial product does not guarantee future results or returns. Securities offered through Robinhood Financial LLC, member FINRA/SIPC. To learn more about the information provided on this page, please see our Web Disclosures.